Furthermore, we also demonstrated that the intraperitoneal administration of the SOCS1 peptidomimetic herein tested in an experimental mouse model of diabetes ameliorated STAT activity and resulted in reduced serum creatinine levels, albuminuria, and improvement of renal histologic changes over time. This evidence concerns the gene SOCS1 and diabetes mellitus.